At AI DiagMe, we help every patient understand their blood test results through artificial intelligence, in clear and accessible language. Because this is health information, the reliability of our content is our absolute priority: every article is produced by a specialized editorial team, then reviewed and validated by doctors. This page explains who we are, how we work, and how we are governed.
Our articles are produced under the editorial responsibility of AI DiagMe. The editorial line and fact-checking are supervised by our senior medical editor, Julien Priour. Every article dealing with a medical topic is then reviewed and validated by a doctor from our scientific and ethics committee. Our content is based on current medical guidelines and peer-reviewed literature.
Responsible for the editorial line and fact-checking.
Co-founder and CEO of AI DiagMe · Senior medical editor · HEC Paris graduate
Julien Priour is the co-founder and chief executive officer of AI DiagMe, where he also serves as senior medical editor, responsible for the editorial line and fact-checking. A graduate of HEC Paris with 3 years of experience in health content editing and verification, he holds the certification “Writing and publishing a scientific article”, issued by the Institut de Recherche pour le Développement (IRD) via France Université Numérique.
He defines the editorial line, the sourcing standards (HAS, Ameli, INSERM…) and the review process applied across the entire site, and ensures that every article complies with current medical guidelines and is validated by a doctor from the scientific and ethics committee.
AI DiagMe's committee brings together 12 independent doctors and experts from a range of specialties — hematology, cardiology, geriatrics, ENT, general medicine, nephrology, internal medicine, endocrinology, pediatrics, gynecology, infectious diseases, medical biology. It validates the medical accuracy of the content and ensures compliance with ethical standards. It is chaired by Dr Sylvain Benzakin.
ENT & head and neck surgery · Facial and neck plastic surgery
Chairs AI DiagMe's scientific and ethics committee. Ensures compliance with the medical validation and ethical governance mandate defined by the charter.
Malignant hematology (lymphomas, myeloma, autologous stem cell transplants, CAR-T therapy). RPPS 10108600593, doctor since 2013.
Five systematic steps, from brief to update, to guarantee medical accuracy and the traceability of every published piece of content.
The committee operates under a written charter ensuring independence and impartiality. Six principles structure its work.
2-year term. A minimum of 5 years of clinical experience is required for each member.
(A) Scientific validation and medical accuracy of content. (B) Ethical governance of AI — algorithmic bias, hallucinations, explainability (compliant with the AI Act).
Mandatory declaration by each member. Reinforced rules for ethical votes.
The committee refrains from any wording resembling a diagnosis, prognosis or therapeutic recommendation. AI DiagMe = health literacy, not a medical device.
Annual activity report summarizing the committee's work.
Dr Sylvain Benzakin — chairs and coordinates the committee's work.
AI DiagMe is a brand of the Smart Medical Care group — Smart Medical Care Ltd (UK, Companies House 15309552, main operating entity & IP owner) and Smart Medical Care SAS (France, RCS Nice 932 924 194, EEA operations).
Processing compliant with GDPR and the AI Act. Health data hosted on Google Cloud, on servers located in France, with an HDS-certified host (Health Data Hosting).
AI DiagMe is an information and health-literacy tool. The content does not replace medical advice: always consult your doctor to interpret your results.
Submitted via the Innovation and Guidance Desk (Guichet Innovation et Orientation, GIO) of the ANSM (the French National Agency for the Safety of Medicines and Health Products) — case 2500297 / GIO 23593272 —, the platform underwent a regulatory qualification analysis.
The ANSM (Directorate for Medical Devices and In Vitro Diagnostic Medical Devices) concluded, on two occasions (responses dated June 30 and July 1, 2025), that AI DiagMe does not meet the definition of a medical device or an in vitro diagnostic medical device (EU Regulations 2017/745 and 2017/746): the solution falls under the general product safety regulation (EU Regulation 2023/988), as a general-use product.
